Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ETX0282 is an orally available, broad spectrum inhibitor of class A and C β-lactamases. Entasis is developing ETX0282 in combination with cefpodoxime proxetil, an orally available cephalosporin approved for treatment of a variety of bacterial infections.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 3,320.00 | |
50 mg | 10-14 weeks | $ 4,380.00 | |
100 mg | 10-14 weeks | $ 6,100.00 |
Description | ETX0282 is an orally available, broad spectrum inhibitor of class A and C β-lactamases. Entasis is developing ETX0282 in combination with cefpodoxime proxetil, an orally available cephalosporin approved for treatment of a variety of bacterial infections. |
Molecular Weight | 315.3 |
Formula | C13H18FN3O5 |
CAS No. | 2209871-83-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ETX0282 2209871-83-8 ETX-0282 4-Me-PDTic hydrochloride ETX 0282 inhibitor inhibit